PRIMARY STUDY
Cannabidiol in Treatment of Autism Spectrum Disorder: A Case Study
Key Findings: This case study reviews a 9-year-old patient with debilitating symptoms related to autism spectrum disorder (ASD) who was treated with a combination of high-dose cannabidiol (CBD) and low-dose tetrahydrocannabinol (THC) oil. Results included a reduction in negative behaviors and an improved quality of life for both the patient and the caregivers.
Type of Study: Meta-analysis
Study Sample Size: 1
Study Result: Positive
Study Location(s): Canada
Year of Pub: 2022
Cannabinoids Studied: Cannabidiol (CBD), Tetrahydrocannabinol (THC), Anandamide (AEA), Fatty Acid Amide Hydrolase (FAAH), 2-Arachidonoyl Glycerol (2-AG), Monoacylglycerol Lipase (MAGL)
Phytocannabinoid Source: Unspecified
Chemotype: Chemotype III
Receptors Studied: CB1, CB2
Sub-Ratio: THC:CBD 1:20
Dosage: CBD 20 mg/mL THC <1 mg/mL Dose: 0.1ml twice daily, increased every three to four days to 0.5ml twice daily
Route of Administration: Oral (Ingestion)
Link to study
